Secret Assets Owners
  • Investing
  • World News
  • Politics
  • Stock
  • Editor’s Pick
World News

Canada says bulk importation not an effective solution to high drug prices in US

by January 9, 2024
January 9, 2024

The Canadian government thinks bulk importation will not provide an effective solution to the problem of high drug prices in the United States after the US Food and Drug Administration allowed Florida to import cheaper drugs from Canada, Health Canada said on Monday.

 

WHY IT’S IMPORTANT

US drug costs are higher than in Canada and other countries where government-run healthcare systems negotiate prices for individual prescription drugs.

Florida on Friday won authorization from the FDA to directly import prescription drugs from Canada, the first state to get such approval for a strategy that could lower prices for medicines.

 

KEY QUOTES

“The Government of Canada is taking all necessary action to safeguard the drug supply and ensure Canadians have access to the prescription drugs they need and has been clear in its position: bulk importation will not provide an effective solution to the problem of high drug prices in the US,” Health Canada said in a statement.

The statement noted regulations to prohibit certain drugs intended for the Canadian market from being sold for consumption outside of Canada if that sale could cause a drug shortage in Canada.

“The Department will not hesitate to take immediate action to address non-compliance, ranging from requesting a plan for corrective measures, issuing a public advisory or other forms of communication, to taking action on the licenses of regulated parties who contravene the export prohibition if warranted.”

 

CONTEXT

In the past, Canada’s government has opposed any US plans to buy prescription medicines, citing threats to the country’s drugs supply or higher costs for its own citizens.

For years, US supporters of importation policy have said buying drugs from elsewhere could help lower costs in the U.S., where more than half of Americans are covered by private health plans.

Florida still needs to submit drug-specific information for FDA review and approval as well as evidence that the drugs it seeks to import have been tested to comply with FDA standards, the agency said. – Reuters

previous post
The Government Can’t Evade Lawsuits by Strategically Mooting Cases
next post
Biden administration to unveil contractor rule that could upend gig economy

You may also like

‘Business as usual’ in Taiwan’s Silicon Valley amid...

July 20, 2025

Automakers want US to move faster on self-driving...

June 27, 2025

Israel and Iran agree on ceasefire to end...

June 24, 2025

G7 abandons joint Ukraine statement as Zelenskiy says...

June 18, 2025

Trump’s tariffs to remain in effect after appeals...

May 30, 2025

Trump delays imposing 50% tariffs on EU until...

May 26, 2025

An aide, a diplomat and a spy: Who...

May 15, 2025

May Day protesters across US decry Trump policies,...

May 2, 2025

IMF slashes global outlook as White House says...

April 23, 2025

Brazil prosecutor general decides not to charge Bolsonaro...

March 28, 2025
Join The Exclusive Subscription Today And Get Premium Articles For Free


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • American history won’t be displayed ‘in a woke manner’ at Smithsonian, Trump says

    August 15, 2025
  • Please Stop Calling them “Reciprocal” Tariffs

    August 14, 2025
  • Energy Department Not Interested In Government Transparency

    August 14, 2025
  • A Bet on X, a Bottle of Scotch, and Why the IRA Was Bound to Break

    August 14, 2025
  • ICE Could Prevent Some of the Coming Corruption, Criminal, and Misconduct Scandals That Will Plague the Agency

    August 14, 2025
  • About us
  • Contact us
  • Terms & Conditions
  • Privacy Policy

Copyright © 2025 SecretAssetsOwners.com All Rights Reserved.


Back To Top
Secret Assets Owners
  • Investing
  • World News
  • Politics
  • Stock
  • Editor’s Pick